L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Circulation

• Publication date

  2000-03-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.101.12.1358PMID 10736276
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome.

  1999cited by this paper
• Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy.

  1999cited by this paper
• Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

  1999cited by this paper
• Nitric oxide synthases in the failing human heart: a doubled-edged sword?

  1999cited by this paper
• Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema.

  1998cited by this paper
• Inhibition of inducible nitric oxide synthase after myocardial ischemia increases coronary flow.

  1998cited by this paper
• Acute effects of nitric oxide and cyclic GMP on human myocardial contractility.

  1997cited by this paper
• Acute Effects of Nitric Oxide and Cyclic GMP on Human Myocardial Contractility 1

  1997cited by this paper
• Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.

  1995cited by this paper
• Increased production of nitric oxide in coronary arteries during congestive heart failure.

  1994cited by this paper

• Cardiometabolic shock: understanding the final turns of the downward spiral

  2025cites this paper
• Multi-target anti-inflammatory and cytotoxic activities of flavonoids from Varthemia iphionoides Boiss. & C. I. Blanche.

  2025cites this paper
• Vascular Endothelial Growth Factor secretion and immunosuppression are distinct potency mechanisms of Human Bone Marrow Mesenchymal Stromal Cells.

  2024cites this paper
• Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

  2024cites this paper
• Dysfunctional and Dysregulated Nitric Oxide Synthases in Cardiovascular Disease: Mechanisms and Therapeutic Potential

  2023cites this paper
• Ammonia detoxification promotes CD8^+ T cell memory development by urea and citrulline cycles

  2022cites this paper
• Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

  2021cites this paper
• Xenocoumacin 2 reduces protein biosynthesis and inhibits inflammatory and angiogenesis-related processes in endothelial cells.

  2021cites this paper
• A novel evaluation of endothelial dysfunction ex vivo: “Teaching an Old Drug a New Trick”

  2021cites this paper
• Vasoactive pharmacologic therapy in cardiogenic shock: a critical review

  2021cites this paper
• Endothelial Dysfunction in Cardiogenic Shock

  2021cites this paper
• Advanced Heart Failure and Cardiogenic Shock

  2020cites this paper
• eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin

  2020cites this paper
• Nitric Oxide and Endothelial Dysfunction.

  2020cites this paper
• Postmyocardial Infarction Cardiogenic Shock

  2019cites this paper
• Translational research in retinal vascular disease. An approach

  2019cites this paper
• Clinical Implications of Monitoring Tissue Perfusion in Cardiogenic Shock

  2018cites this paper
• Effectiveness of L-arginine or nitric oxide as a reactivator and an antidote against cholinesterase pesticides and other toxic substances

  2018cites this paper
• Einsatz von Vasopressoren und Inotropika im kardiogenen Schock

  2017cites this paper
• Endothelial nitric oxide synthase polymorphism and prognosis in systolic heart failure patients.

  2015cites this paper
• Death and Interventional Cardiology: A Tale of 2 Trials

  2014cites this paper
• Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases.

  2014cites this paper
• Pro-oxidative effects of aggregated transthyretin in human Schwannoma cells.

  2013cites this paper
• Post Infarction Cardiogenic Shock: Is It Clinically Important to Differentiate Hemodynamic Patterns?

  2013cites this paper
• Cardiogenic Shock Complicating Myocardial Infarction: An Updated Review

  2013cites this paper
• Nitrates for acute heart failure syndromes.

  2013cites this paper
• Post Myocardial Infarction Cardiogenic Shock

  2013cites this paper
• Estado de shock cardiogénico

  2012cites this paper
• État de choc cardiogénique

  2012cites this paper
• Transthyretin Aggregates Induce Production of Reactive Nitrogen Species

  2012cites this paper
• Monitoring bei infarktbedingtem kardiogenen Schock

  2011cites this paper
• MOLECULAR AND CELLULAR STUDIES OF TRANSTHYRETIN AND RELATED AMYLOID PATHOGENESIS

  2011cites this paper
• New investigational drugs for the management of acute heart failure syndromes.

  2010cites this paper
• Case report: methylene blue for cardiogenic shock

  2010cites this paper
• Cardiogenic shock: The role of inflammation

  2010cites this paper
• Choque Cardiogénico de origen isquémico

  2010cites this paper
• Management of cardiogenic shock: focus on tissue perfusion.

  2009cites this paper
• Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance

  2009cites this paper
• Choque Cardiogénico de origen isquémico

  2009cites this paper
• Choc cardiogénique de l'infarctus du myocarde

  2009cites this paper
• Post-resuscitation NOS inhibition does not improve hemodynamic recovery of hypoxic newborn pigs

  2009cites this paper
• Which Therapy for Which Condition

  2009cites this paper
• Inducible Nitric Oxide Synthase Expression and Cardiomyocyte Dysfunction During Sustained Moderate Ischemia in Pigs

  2008cites this paper
• A Review of Cardiogenic Shock in Acute Myocardial Infarction

  2008cites this paper
• Nitric oxide synthase inhibitors in cardiogenic shock: present and future.

  2008cites this paper
• Cardiogenic shock: basics and clinical considerations.

  2008cites this paper
• Cardiogenic shock.

  2008cites this paper
• Expert opinion on tilarginine in the treatment of shock

  2008cites this paper
• The microcirculation in health and critical disease.

  2008cites this paper
• Is persistent hypotension after transient cardiogenic shock associated with an inflammatory response?

  2008cites this paper
• Nitric Oxide Synthase Inhibitor (MTR-105) during Open-Heart Surgery

  2008cites this paper
• Genetic dilemma: eNOS gene intron 4a/b VNTR polymorphism in sepsis and its clinical features in Turkish children.

  2008cites this paper
• Methylene blue and vasoplegia: who, when, and how?

  2008cites this paper
• REVIEWARTICLE Diastolic heart failure in anaesthesia and critical care

  2007cites this paper
• Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.

  2007influential citation
• Causes of death and re‐hospitalization in cardiogenic shock

  2007cites this paper
• Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons.

  2007cites this paper
• Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock.

  2007cites this paper
• Abstracts of the 5th International Meeting on Intensive Cardiac Care, October 14-16, 2007, Tel Aviv, Israel.

  2007cites this paper
• Cardiogenic shock: treatment.

  2007cites this paper
• Invited Synopses

  2007cites this paper
• [Multidisciplinary approach to the treatment of cardiogenic shock].

  2007cites this paper
• Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.

  2007cites this paper
• The Tragedy of TRIUMPH for Nitric Oxide Synthesis Inhibition in Cardiogenic Shock

  2007cites this paper
• Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock—Reply

  2007cites this paper
• Percutaneous Coronary Intervention for Acute Myocardial Infarction

  2007cites this paper
• Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study.

  2007cites this paper
• Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction

  2007cites this paper
• Cardiogenic shock complicating myocardial infarction.

  2007cites this paper
• Mediators of anaphylaxis.

  2007cites this paper
• Tests for 2 x 2 Tables in Clinical Trials

  2007influential citation
• Stati di shock

  2007cites this paper
• Cardiac surgery and cardiology Multidisciplinary approach to the treatment of cardiogenic shock

  2007cites this paper
• Nitric oxide and cardiovascular risk factors

  2007cites this paper
• Pathophysiology of cardiogenic shock complicating acute myocardial infarction.

  2007cites this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cites this paper
• The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target.

  2006cites this paper
• Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.

  2006cites this paper
• The evaluation and management of cardiogenic shock.

  2006cites this paper
• Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cites this paper
• [Intensive care medicine: after positive studies questions occur].

  2006cites this paper
• Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect--a Chinese concept for a worldwide pandemic.

  2006cites this paper
• Nitric oxide synthase inhibitors in post‐myocardial infarction cardiogenic shock—an update

  2006cites this paper
• Cardiogenic shock – an inflammatory disease

  2006cites this paper
• Acute decompensated heart failure: formulating an evidence-based approach to diagnosis and treatment (part II).

  2006cites this paper
• Nitric oxide and cardiovascular system.

  2006cites this paper
• États de choc

  2006cites this paper
• Anestezjologia i intensywna terapia How can we increase chances of the patient in cardiogenic shock

  2006cites this paper
• Strengthening community consultation in critical care and emergency research

  2006cites this paper
• Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.

  2006cites this paper
• Cardiogenic shock--Beyond the large infarction.

  2006cites this paper
• Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction*

  2006cites this paper
• Intensivmedizin - Nach den positiven Studien kommen die Fragen

  2006cites this paper
• Acute decompensated heart failure: formulating an evidence-based approach to diagnosis and treatment (part I).

  2006cites this paper
• Methylene blue added to a hypertonic–hyperoncotic solution increases short-term survival in experimental cardiac arrest*

  2006cites this paper
• Pathophysiology of Coronary Artery Disease

  2005cites this paper
• Attenuation of postoperative noradrenaline need by nitric oxide inhibition using L‐NMMA

  2005cites this paper
• Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock.

  2005cites this paper
• Nitric oxide and cardiac remodeling.

  2005cites this paper
• Management of Cardiogenic Shock Attributable to Acute Myocardial Infarction in the Reperfusion Era

  2005cites this paper